#VEGF
Think of VEGF as fertiliser for cancer cells.

🤦🏻‍♀️
November 15, 2026 at 11:15 PM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight - IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy.
doi.org/10.1093/abt/...
#bispecific #bispecificantibody #bispecificantibodies #bsab #bsabs #vegf #pdl1 #adcc #adcp
November 20, 2026 at 3:06 PM
VEGF is stuff that makes new blood vessels grow.

Too much of this stuff and you help tumour cells to grow. So… cancer.
November 15, 2026 at 10:24 PM
INSERM researchers analyzed longitudinal samples from 221 patients recovering from severe COVID.

Persistent VEGF-A signaling was associated with delayed recovery and experimentally triggered release of clotting-related vesicles from endothelial cells.
November 15, 2026 at 12:00 AM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight - Mass photometry reveals stoichiometry and binding dynamics of bispecific tetravalent anti-VEGF–PD-1 antibody ivonescimab.
doi.org/10.1093/abt/...
#mab #ivonescimab
November 20, 2026 at 3:10 PM
Disappointing -- but not unexpected -- news. This isn't the end of the line for ivonescimab or the PD-1/VEGF bispecific antibody strategy.

www.cancerhealth.com/article/fda-...
FDA Rejects Approval of Ivonescimab for Advanced Lung Cancer
The PD-1/VEGF bispecific antibody delayed disease progression but did not significantly improve survival in a global Phase III study.
www.cancerhealth.com
November 16, 2026 at 9:32 PM
youtube.com/watch?v=VEGF...

Texas has handed Elon Musk’s companies about $1.7 billion in tax breaks and grants, including a massive incentive package for the planned Terafab chip facility. Musk then poured at least $225 million into Texas politics, only to watch Republicans lose control.
He Just Stole BILLIONS From Them...
YouTube video by The Ring of Fire
youtube.com
November 18, 2026 at 6:11 PM
Ophthopedia Update: Authors’ Reply: Impact of Intravitreal Anti-VEGF Injections on Cataract Development: We appreciate the thoughtful comments by Cao et al1 regarding our recent study on the risk of cataract surgery associated with long-term intravitreal… #Ophthalmology #ophthotwitter #eyecare
Authors’ Reply: Impact of Intravitreal Anti-VEGF Injections on Cataract Development
We appreciate the thoughtful comments by Cao et al1 regarding our recent study on the risk of cataract surgery associated with long-term intravitreal anti-VEGF therapy. We welcome this opportunity to address their points.
dlvr.it
November 20, 2026 at 9:31 PM
Over 1.1 million injections reveal no increased serious ocular safety risks with combined anti-complement and anti-VEGF therapy in AMD. #AMD #Retina #Complement #AntiVEGF 🔗 buff.ly/6l5GLfl
November 16, 2026 at 10:00 AM
New hope for the tiniest preemies. We’re moving from late laser & anti-VEGF to topical propranolol and β3-receptor agonists that actually guide normal retinal vessels. Precision neonatology is here.

link.springer.com/article/10.1...

#ROP #Neonatology #Preterm #Retina
November 18, 2026 at 3:31 AM
Ophthopedia Update: Incidence and risk factors for epiretinal membrane formation after intravitreal anti-VEGF injection in branch retinal vein occlusion: WHAT IS ALREADY KNOWN ON THIS TOPIC

*

Anti-vascular endothelial growth factor (VEGF) therapy is the… #Ophthalmology #Ophthotwitter #BJO
Incidence and risk factors for epiretinal membrane formation after intravitreal anti-VEGF injection in branch retinal vein occlusion
WHAT IS ALREADY KNOWN ON THIS TOPIC * Anti-vascular endothelial growth factor (VEGF) therapy is the standard treatment for branch retinal vein occlusion (BRVO)-related macular edema. Recently, cases of rapidly progressive epiretinal membranes (ERMs) have been reported after anti-VEGF injections. However, the incidence and risk factors for ERM formation following anti-VEGF therapy remain poorly defined.WHAT THIS STUDY ADDS * This longitudinal cohort study showed that 22% of BRVO eyes developed a new ERM within 1 year after anti-VEGF injection. Post-injection posterior vitreous detachment (PVD) was consistently associated with ERM development in multivariable analyses.HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY * Our findings support closer monitoring of the changes of the vitreoretinal interface after anti-VEGF therapy in eyes with BRVO. Further studies on the mechanisms linking macular edema dynamics, PVD and subsequent ERM formation are needed.Introduction A retinal vein occlusion (RVO) is one of the leading causes of vision reduction in...
dlvr.it
November 17, 2026 at 5:50 PM
🔥WoS #HighlyCitedPaper
Blocking Tumoral #Angiogenesis VEGF/VEGFR Pathway: #Bevacizumab—20 Years of Therapeutic Success and Controversy
✍️by Elena Chitoran, Vlad Rotaru et al.
📊38 citations
Read here📖 www.mdpi.com/2072-6694/17...
#VEGF
November 18, 2026 at 5:17 AM
I LOVE TEXANS 🩵💙

youtube.com/watch?v=VEGF...
Texans Are FURIOUS After Musk Did This...
YouTube video by The Ring of Fire
youtube.com
November 18, 2026 at 11:52 PM
Today at 3 pm CT, explore the evolving PD-1/VEGF bispecific landscape with SITC! Discuss survival endpoints, toxicity, mechanistic rationale, regulatory considerations and how comparative benefit, patient access and development risk shape commercial value. Register: https://ow.ly/44Jb5108rhj
November 20, 2026 at 4:00 PM
Kodiak (KOD) develops Zenkuda (tarcocimab), a retinal anti-VEGF with five positive Phase 3s; multi-indication BLA planned Q4 2026. Baker Bros bought $24.3M at $98.51 on Nov 4. Risk: cash $88.7M at Sep 30 plus ~$69M ATM; going-concern language.
November 21, 2026 at 12:01 PM
Explore the evolving PD-1/VEGF bispecific landscape with SITC! Discuss survival endpoints, toxicity, mechanistic rationale, regulatory considerations and how comparative benefit, patient access and development risk shape commercial value. Register: https://ow.ly/aMKn5107OaJ
November 18, 2026 at 6:30 PM
Ophthopedia Update: Weekly Journal Update — November 18, 2026: Access to intravitreal anti-VEGF therapy in Medicare plans, SC-CPC vs micropulse laser surgery, detecting strabismus and amblyopia with AI, highly aspherical lenslets that may slow myopia progression, the failure… #Ophthalmology #News
Weekly Journal Update — November 18, 2026
Access to intravitreal anti-VEGF therapy in Medicare plans, SC-CPC vs micropulse laser surgery, detecting strabismus and amblyopia with AI, highly aspherical lenslets that may slow myopia progression, the failure rates of procedures for secondary glaucoma.
dlvr.it
November 18, 2026 at 5:14 PM
𝗧𝗢𝗗𝗔𝗬: ISN-ASON webinar: Management of anemia in cancer patients and VEGF inhibitors related kidney adverse events

🗣️ Verônica Torres, Shveta Motwani, Shuchi Anand, Anushree Shirali
👥 @sabinekaram.bsky.social
🗓️ November 19
🕑 14:00 CET
🔗 Free registration: https://bit.ly/4i6l9XJ
November 19, 2026 at 6:00 AM